$SRRK

FLIER JEFFREY S. sold $164K of SRRK

FLIER JEFFREY S. sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.53–$54.88, $0.16M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FLIER JEFFREY S.
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosed open-market sale by a director, executed under a pre-arranged 10b5-1 plan, is typically not a standalone fundamental driver for the stock.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not state whether the director’s remaining holdings changed meaningfully versus prior plans, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 for a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp (SRRK).

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding director Jeffrey S. Flier sold about 3,053 shares in open-market transactions under a 10b5-1 plan, totaling $164,490.

Expected impact

Limited near-term impact; any effect is likely short-lived unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director sale under 10b5-1.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the 10b5-1 designation materially lowers that probability.

Key entities

  • Scholar Rock Holding Corp

    Company whose director insider sale is disclosed via SEC Form 4.

  • FLIER JEFFREY S.

    Director who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

$SRRKMed

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.